Sunday, 15 September 2013

China antitrust officials investigate Bayer

Article China antitrust officials investigate Bayer

World News | September 13, 2013


Bayer has confirmed that officials in China have made inquiries into a potential case of unfair competition.
Oliver Renner, head of global corporate communications and public affairs at the German major, told PharmaTimes that a local branch of the AIC (Administration for Industry and Commerce) “visited one of our offices in China at the end of August to investigate a potential case of unfair competition”. He added that “we are fully cooperating with the authority” and Bayer is committed to investigating the issue internally.

No further details have been disclosed about the probe but the move comes as part of China's investigations into the pharmaceutical sector as a whole regarding alleged corruption. The most high-profile cases to date have involved GlaxoSmithKline, most notably a charge that the company made payments to travel agencies which were then used to bribe doctors.

News of the Bayer probe came after the country’s Central China Television broadcast a report alleging that a subsidiary of Sino Biopharmaceutical, Chia Tai-Tianqing Pharmaceutical, offered holidays in Taiwan and Thailand to doctors. It is the first publicised case of the Chinese government investigating a local drugmaker rather than a multinational.

Friday, 13 September 2013

US FTC organizes a workshop with the theme 'The Internet of Things'


Jason Hicks from Antitrust and Distribution Law Blog  advices that in order to avoid an FTC enforcement action, a company selling devices that connect to the Internet should carefully review its products and data security policies to ensure that present practices adequately protect consumer privacy.


Read more here.

Tuesday, 3 September 2013

Slovak Antimonopoly Office fined the participant to the freight rail transport market

(Bratislava, September 3, 2013, Extract from news release

On August 22, 2013 the Antimonopoly Office of the Slovak Republic, Division of Abuse of Dominant Position and Vertical Agreements (hereinafter only „the Office“) issued a decision on restriction on the market of freight rail transport. The dominant company abused its position by adopting exclusionary strategy consisting of restriction of leasing/selling of electric locomotives and restriction of refueling motor locomotives for competitors in such a way that it has distorted competition on the market. The Office imposed a fine in the amount of EUR 10 253 662 for violation of competition rules.
A necessary pre-condition for the carriers to provide freight rail transport services is to have access to locomotives, which could be either electric or diesel. The electric ones are, however, more effective than the diesel ones. The electric locomotives capable to operate in the Slovak Republic are predominantly owned by the dominant which did not want to sell/rent them to its rivals. Hence, the private carriers have been increasingly using the less effective diesel locomotives. Diesel locomotives need regular refuel of oil, however the network of fuel-stations for diesel locomotives is owned by the dominant, which did not allow private carriers to refuel at their fuel-stations. Behaviour of the dominant, which was fined by the Office, increased costs of competing carriers. Carriers were not able to effectively provide their services, succeed on the market, grow and compete with the dominant.
 
The decision is not valid yet. As it is a first-instance decision and the party to the proceedings may submit an appeal, the Office does not provide any details on the subjected decision for the time being.

Monday, 2 September 2013

A-apoteket:s decision to expel Uldum Apotek is illicit according to Danish CA



Matas is the largest health and beauty retailer in Denmark. It offers a distinctive one-stop retail concept which serves a broad range of health, beauty, household and personal care needs. The Matas Store Network consists of a network of 293 Matas stores in Denmark.

A-apoteket is the biggest pharma retail chain in Denmark comprising 112 pharmacies, 35 branches and 58 outlets.

In 2011 the Danish legislation was amended allowing the pharmacists to freely establish so-called “medicine delivery points” all over the country. A medicine delivery point is normally established in cooperation with a different company, e.g. a supermarket, as a “shop-in-shop” concept. Uldum Apotek took advantage of the change and made an agreement with Matas. Uldum Apotek is a former member of A-apoteket, Denmark’s largest purchasing association for pharmacists.

A-apoteket decided to oust Uldum Apotek because of the partnership with Matas – even though A-apoteket is only involved in negotiating discount deals on non-pharmaceuticals and the partnership with Matas was limited to pharmaceuticals, i.e. the partnership concerned a different product market.

The Danish Competition Authority expressed concerns that a decision to prohibit a member to establish medicine delivery points in Matas’ shops, and to expel the member for refusing to comply with the exclusion, could significantly restrict competition on the pharmaceutical markets. Especially taken into account that (I) the establishment of medicine delivery points are the only real way for pharmacists to compete, (II) Matas is one of the most obvious partners for such an enterprise and (III) the partnership with Matas did not appear to negatively influence A-apoteket’s work, and thus the decision made by A-apoteket could not be considered ancillary to the operation of A-apoteket.

Competition Authority welcomes the undertakings given in the High Court today by the IMO to suspend the decision of its Committee to withdraw from providing certain services to patients

The Competition Authority (Thursday 11th July 2013) confirmed that it has issued a warning to the Irish Medical Organisation (IMO) which represents general practitioners (GPs). This warning relates to a reported decision of the IMO of 10th July threatening collective action, including the possible withdrawal of certain services by its members.

An IMO press release issued on 10th July 2013 stated that at a meeting of its GP committee on 8th July 2013, it passed a motion that unanimously condemned the reduction in GP fees which the Government proposes to introduce under the Financial Emergency Measures in the Public Interest Act 2009. In particular, the GP Committee decided at that meeting to immediately withdraw from:

  • Primary Care Teams; 
  • Community Intervention Teams, and 
  • Clinical Care Programmes (Chronic Disease).
Section 4 of the Competition Act and Article 101 of the Treaty on the Functioning of the European Union prohibit agreements among undertakings that have the object or effect of restricting or distorting competition. The Authority considers that these competition law prohibitions apply to self-employed GPs. The Authority further considers that an agreement to take collective action or any subsequent collective action on foot of such agreement breaches Section 4 and/or Article 101 of the Treaty. This is consistent with the view that the Authority has taken in previous cases involving trade associations representing pharmacists, hauliers, travel agents and veterinary surgeons.

The Competition Authority has written to the IMO setting out its objection to this alleged breach of competition law in this instance. The Authority has advised that it intends to take all necessary enforcement action if the IMO fails to rescind its decision concerning the withdrawal of services. The Authority has requested that the IMO immediately remove the press release and publish on its website an open undertaking to reverse this decision.

The Authority has issued this press release, both as a form of public notice to
GPs generally, and to indicate the Authority’s commitment to oppose vigorously collective market behaviour by competitors that prevents, restricts or distorts competition.
--------


The Competition Authority has confirmed it has commenced legal proceedings against the Irish Medical Organisation (IMO) following their refusal to rescind a decision of its GP Committee made on 8 July 2013 to withdraw certain GP patient services in protest at proposed Government cuts to fees paid to GPs under the GMS contract.
The IMO’s decision was made at a meeting of its GP Committee and was the subject of a press release published by the IMO on 10 July.  The Authority had given the IMO until 12 o’clock yesterday to remove the press release relating to the decision from their website and to publish an undertaking to reverse the decision.  Following the expiry of the deadline, the Authority received correspondence from the IMO’s solicitors stating that the IMO would not be complying with the Authority’s request. 
In light of this development, the Authority has today filed papers in the High Court seeking (i) a declaration that the IMO’s decision to withdraw the services concerned with a view to preventing the Minister for Health and Children from reducing the fees payable under the GMS contract is prohibited under both Irish and EU competition law and is therefore void and (ii) an interlocutory injunction requiring the IMO to retract and rescind its decision of 8 July and not to issue any further decisions to the same or similar effect and (iii) to remove from the IMO’s website its press release of 10 July relating to this matter and to publish on its website an open undertaking to reverse its decision of 8 July.
The relevant papers are being served on the solicitors acting for the IMO in this matter.
The hearing of the Authority’s interlocutory application is expected to take place within the next week.
--------
The Competition Authority welcomes the undertakings given in the High Court today by the Irish Medical Organisation (IMO) to suspend the decision of its GP Committee dated 8 July 2013 to withdraw from providing certain services to patients.  The IMO’s decision was in opposition to proposed Government cuts to fees paid to GPs under the General Medical Scheme (GMS).
Pending the outcome of proceedings in the High Court, the IMO has undertaken:
(i) to suspend the decision of its GP Committee dated 8 July 2013, referred to in the statement of 10 July 2013 (the Statement), relating to the collective withdrawal of certain medical services by General Practitioners, by close of business on 24 July 2013
(ii) to remove the Statement from its website by close of business on 24 July 2013
(iii) to inform all of its members of the giving of these undertakings no later than close of business on 25 July 2013.
This means that GPs cannot now collectively withdraw from providing the services referred to in the IMO Statement to patients pending the outcome of the proceedings initiated by the Authority.  The Authority initiated the proceedings because it believed that the collective withdrawal of these services would have a negative impact on patients and was an attempt to fix the fees paid to GPs under the GMS contract.  The Authority took the view that such action infringes both Irish and EU competition law.